CONTACT US
contact us
logotype
CONTACT US

Have a Project in Mind? Say Hi!

  • Mon - Sun: 10am - 10pm
  • 27 Division St, New York,
    NY 10002, USA​
HomeGrid 2 Columns
Grid 2 Columns
October 2, 2024
Drug Delivery BusinessBY admin

Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy

READ MORE
October 1, 2024
PR NeweswireBY admin

Qnovia, Inc. announces FDA clearance of IND application for lead asset RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy

READ MORE
April 9, 2024
Business WireBY admin

Qnovia, Inc. Announces the Appointment of Four New Members to its Scientific Advisory Board

READ MORE
December 4, 2023
Medical Device NetworkBY admin

Qnovia’s inhaled smoking cessation therapy triumphs in first clinical study

READ MORE
November 30, 2023
Business WireBY admin

Qnovia, Inc. announces positive results from first-in-human pharmacokinetic and safety study of lead asset QN-01, a prescription inhaled smoking cessation therapy

READ MORE
October 19, 2023
Business WireBY admin

Qnovia Enters Collaboration with University of Virginia to Advance Inhaled Drug Candidates for Treating Infectious Diseases

READ MORE
#side-panel.side-panel {width: 500px;}#side-panel.side-panel .side-panel_sidebar {padding: 70px 0px 50px 60px;background-color: #FFFFFF;} Qnovia